Last updated on 4-11-2022 by Géraldine Daneau
Auteurs
Andreas Jung; Annalisa Orenti; Fiona Dunlevy; Elina Aleksejeva; Egil Bakkeheim; Vladimir Bobrovnichy; Siobhán B Carr; Colombo, Carla; Corvol, Harriet; Rebecca Cosgriff; Géraldine Daneau; Deniz Dogru; Pavel Drevinek; Vukic, Andrea Dugac; Isabelle Fajac; Alice Fox; Stojka Fustik; Gulmans, Vincent; Harutyunyan, Satenik; Hatziagorou, Elpis; Irena Kasmi; Hana Kayserová; Elena Kondratyeva; Krivec, Uroš; Halyna Makukh; Malakauskas, Kestutis; Edward F McKone; Mei-Zahav, Meir; de Monestrol, Isabelle; Hanne Vebert Olesen; Rita Padoan; Parulava, Tsitsino; Maria Dolores Pastor-Vivero; Luísa Pereira; Guergana Petrova; Andreas Pfleger; Liviu Pop; Jacqui G van Rens; Milan Rodic; Marc Schlesser; Valérie Storms; Oxana Turcu; Lukasz Woz Niacki; Panayiotis Yiallouros; Zolin, Anna; Damian G Downey; Naehrlich, LutzTrefwoorden
Article written during project(s) :
Samenvatting:
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis (pwCF) can lead to severe outcomes.
METHODS: In this observational study, the European Cystic Fibrosis Society Patient Registry collected data on pwCF and SARS-CoV-2 infection to estimate incidence, describe clinical presentation and investigate factors associated with severe outcomes using multivariable analysis.
RESULTS: Up to December 31, 2020, 26 countries reported information on 828 pwCF and SARS-CoV-2 infection. Incidence was 17.2 per 1000 pwCF (95% CI: 16.0-18.4). M…